Leukemia relapse is a major cause of treatment failure after allogeneic bone marrow transplantation. We administered recombinant interleukin-2 (rIL-2) to a patient who relapsed after unrelated allogeneic bone marrow transplantation (uBMT). While the number of peripheral blood monoblastic leukemia cells increased after administration of rIL-2, the patient achieved durable remission for 5 months after low-dose chemotherapy followed by adoptive transfer of engrafted graft-derived lymphokine-activated killer (LAK) cells. Following the disappearance of the blast cells, however, both cutaneous and liver GVHD were exacerbated. Administration of rIL-2 and adoptive transfer of graftderived LAK cells are considered to be possible choices for the treatment of acute leukemia relapsing after uBMT when donor leukocyte transfusion is not available. Keywords: rIL-2; GVHD; LAK cells; uBMT; refractory acute monoblastic leukemia
A 24-year-old woman suffering from refractory acute monoblastic leukemia (FAB; AML-M5b) with cutaneous infiltration by leukemia cells was referred to our hospital in September 1993. Her blast cells were characterized by expression of CD4, CD13, CD14, CD33 and HLA-DR. Five courses of intensive chemotherapy and total skin electron-beam irradiation (TSEBI) did not result in durable remission as shown in Figure 1 . Allogeneic bone marrow transplantation from an HLA-matched unrelated donor (uBMT) was performed. The conditioning regimen consisted of total body irradiation (TBI) in twice-daily 300 cGy fractions for 2 days on days Ϫ9 and Ϫ8, with recombinant granulocyte colony-stimulating factor (rG-CSF) combined high-dose cytosine arabinoside (ara-c) 3 g/m 2 twice daily i.v. on days Ϫ6 and Ϫ5 (total four doses) and cyclophosphamide 60 mg/kg once daily i.v. on days Ϫ4 and Ϫ3 (total 120 mg/kg), and prophylaxis for graft-versus-host disease (GVHD) was performed with i.v. cyclosporine (CYA) and short-term methotrexate (MTX) as reported previously.
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Absolute neutrophil counts rose above 500 mm 3 on day ϩ19, and grade II acute GVHD (skin ϩϩϩ) was noted. On day ϩ39, cutaneous induration was noted and skin biopsy showed the subcutaneous infiltration of leukemia cells without any evidence of leukemia relapse in bone marrow (leukemia cutis). CYA was discontinued to augment the graft-versus-leukemia (GVL) effects. As the skin erythema became worse, she was given prednisolone (PSL) 2 mg/kg/day i.v. On day ϩ88, bone marrow examination showed relapsed monoblastic leukemia and i.v. administration of intermediate-dose cytosine arabinoside (IDra-C) 1 g/m 2 twice daily i.v. for 4 consecutive days was started. However, the relapsed leukemia was not controlled well with this regimen. With the patient's informed consent, continuous low-dose rIL-2 (2.6 ϫ 10 5 IU/m 2 /day, Shionogi Pharmacy, Osaka, Japan) was administered i.v. to enhance the GVL effects, but was discontinued because of the appearance of high fever over 40°C with an elevated level of C-reactive protein, malaise, nausea, vomiting and socalled 'capillary leak syndrome' characterized by lung edema with alveolar capillary block, weight gain and oliguria. Surprisingly, her monoblastic cell number began to increase soon after the administration of rIL-2. Etoposide (VP-16) 100 mg was administered i.v. on days ϩ104 to ϩ108 to reduce the number of blast cells. In vitro 3 HTdR uptake study revealed that her blast cells responded to rIL-2 and expressed high levels of IL-2 receptor ␤ chain by fluorescence-activated cell sorter analysis (data not shown). Her blast cells responded to administration of a very low dose of VP-16. After the oral administration of VP-16 50 mg/day on days ϩ137 to ϩ139, and VP-16 100 mg/day on days ϩ154 to ϩ156, durable hematological remission was obtained. When the donor-derived graft function was recovered, however, her cutaneous GVHD reappeared and skin biopsy specimen showed lichenoid changes. On day ϩ183, her peripheral blood mononuclear cells were collected by leukapheresis and cultured in RPMI 1640 containing 5% human AB serum and rIL-2 1000 IU/ml for 3 weeks. Cultured lymphocytes and the supernatant were negative for bacteria, fungus, mycoplasma and endotoxin. With the patient's informed consent, 3.9 ϫ 10 7 cells/kg of graft-derived LAK cells were administered on day ϩ215 of transplantation. Studies for cytochemical analysis and NK/LAK activity for her peripheral blood lymphocytes were performed as previously described, and the results did not show any immunological changes before or after the infusion of LAK cells (Figure 2 ). She was discharged from our hospital on day ϩ234 and maintained durable remission for a further 5 months. During her follow-up period in our outpatient clinic, she was gradually noted to have extensive chronic GVHD which became intolerable. CYA and PSL were restarted on day ϩ273 followed by the appearance of bone marrow relapse on day ϩ365. On day ϩ457 she died due to relapsed leukemia and systemic fungal infection. Discussion rIL-2 administration for AML patients has been reported by several groups, 2 and some cases with low tumor burden in their bone marrow responded well to rIL-2 and achieved durable remission. Several reports showed the effective use of a combination of rIL-2 and IFN-␣ for the treatment of relapsed leukemia after allogeneic BMT. 3 The Seattle and Dana-Faber groups [4] [5] [6] reported administration of low-dose rIL-2 combined with autologous, syngeneic, T cell-depleted or T cell-replete bone marrow transplantation as a prophylaxis for relapsed leukemia with favorable results. After engraftment, the patient's peripheral blood lymphocytes were reconstituted from the bone marrow graft, and became of donor origin in most cases. Apheresis seemed to be very helpful for the concentration of donor origin, graft-derived allogeneic lymphocytes. In vitro priming of graft-derived LAK cells and adoptive transfer is a feasible treatment for many cases who did not have any available donor lymphocytes.
In our case, the myelomonocytic leukemia cells responded to rIL-2 and showed marked proliferation. Bosco et al 7 reported that the IL-2 receptor (IL-2R) ␥ chain was also expressed on cells of the monocytic lineage. Monocytes were also reported to express the IL-2R␤ chain constitutively and IL-2R␥ chain after stimulation with cytokines such as IL-2, interferon-␥ (IFN-␥), or transforming growth factor-␤ (TGF-␤). Medium affinity IL-2R consisting of both ␤ and ␥ chains was thus considered to be expressed on the monocytes. Several studies showed that rIL-2 could increase the susceptibility of leukemia cells expressing IL-2R to chemotherapeutic reagents. [8] [9] [10] Our case showed that leukemia cells were resistant to high-dose cytosine arabinoside, but became responsive to low-dose VP-16 after exposure to rIL-2. rIL-2 might have induced cell-cyling of the patient's leukemia cells and helped to make them more susceptible to VP-16.
The clinical effects of the adoptive transfer of autologous LAK cells, without simultaneous systemic administration of rIL-2, are not clear in our patient. We speculate that the gradual progression of GVHD after the infusion of LAK cells accompanied by the suppression of blast cell number for approximately 3 months, could be due to the GVL effects induced against the relapsed leukemia. Further case studies including the documentation of in vivo increases in cytotoxic effectors against the autologous leukemia cells are required to confirm the anti-leukemia effects of LAK cells for relapsed leukemia after allogeneic BMT.
As the infusion of donor lymphocytes, a potential current therapeutic choice for this distress condition, usually cannot be practically performed for patients receiving bone marrow cells from unrelated donors, rIL-2 combined chemotherapy for IL-2-sensitive leukemia cells followed by the infusion of LAK cells can be considered as another therapeutic choice to augment GVL effects. The prolongation of antileukemia effects, however, is the next important issue to overcome, and further clinical investigations are required.
